This month we are dissecting an article from The New England Journal of Medicine – Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.

The AMPLITUDE-O trial evaluated the cardiovascular and renal outcomes of efpeglenatide in patients with type 2 diabetes. This Journal Club CE discusses the trial and whether efpeglenatide extends similar protective cardiovascular and renal effects as already existing GLP-1 receptor agonists.

Upon successful completion of this application-based course, pharmacists and pharmacy students should be able to:
1. Compare and contrast the mechanism of action of efpeglenatide versus other GLP-1 agonists.
2. Discuss how the outcomes of the AMPLITUDE-O trial were incorporated into the Standards of Medical Care in Diabetes-2022.
3. Interpret the safety and efficacy data on efpeglenatide’s effect on cardiovascular and renal outcomes in the AMPLITUDE-O trial
4. Evaluate strengths and limitations of the AMPLITUDE-O trial
5. Evaluate efpeglenatide’s place in therapy for the care of a patient with Type 2 Diabetes.

Emily Van Klompenburg, PharmD, BCACP
Assistant Professor
South Dakota State University College of Pharmacy and Allied Health Professions

Emily Van Klompenburg has no relevant financial relationships to disclose. 

To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read:

Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med. 2021 Sep 2;385(10):896-907. doi: 10.1056/NEJMoa2108269. Epub 2021 Jun 28. PMID: 34215025.

*CEimpact provides you with two (2) opportunities to complete the exam. If there are two failed attempts, the participant will not receive CPE credit.

Fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: June 8, 2022
Planned Expiration Date: June 8, 2025

RV2-3.24